Ibandronate Sodium Catalog No.:M8787-2 000-fold selective for 20 other

000-fold selective for 20 other human methyltransferases

3 μM BDP5290 completely inhibits myosin II light chain (MLC) phosphorylation induced by MRCKβ

NIBR3049 exhibits IC50 values of 1

is an ASIC blocker

Ibandronate Sodium Catalog No.:M8787-2 000-fold selective for 20 otherIbandronate sodium is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). Ibandronate is indicated for the treatment and prevention of osteoporosis in post menopausal women. In May 2003, the U. S. Food and Drug Administration (FDA) approved